McKesson Reports Strong Q2 2027 Results Driven by GLP-1 Growth and Raises Fiscal Guidance
McKesson (MCK) delivered robust second-quarter fiscal 2027 results, reporting revenue of $111.0 billion, an 8% increase year-over-year. The growth was primarily fueled by volume increases in the North American Pharmaceutical segment and the Oncology & Multispecialty division. Notably, GLP-1 medication revenue surged 26% to $16 billion, reflecting high demand for specialty products. Driven by strong first-half performance, management raised its full-year fiscal 2027 adjusted EPS guidance to a range of $45.60 to $46.40. The company also highlighted strategic expansion through the $2.25 billion acquisition of Precision Medicine Group and a significant investment in Option Care Health. While Medical-Surgical Solutions saw an operating profit decline due to product mix, overall operational leverage improved significantly.
Topics: EPS beat GLP-1 medications guidance raise pharmaceutical distribution revenue growth
Read the full article at Motley Fool
Part of the story Cardinal Health Reports Strong Q1 Fiscal 2027 Results and Raises Annual EPS Guidance (27 articles)